Table 3 Initial patients’ characteristics for PV, ET, and PMF
From: MPL W515 L/K mutations in myeloproliferative neoplasms
Variables (clinical and laboratory findings) | Polycythemia Vera (PV) N = 14 | Essential thrombocythemia (ET) N = 26 | Primary myelofibrosis (PMF) N = 20 | P value |
|---|---|---|---|---|
Female, no. (%) | 6 (42.9) | 13 (50) | 7 (35.0) | 0.597 |
Male, no. (%) | 8 (57.1) | 13 (50) | 13 (65.0) | |
Age | ||||
Mean ± SD | 47 ± 13.6 | 47 ± 14 | 53.6 ± 12.6 | 0.236 |
Median | 49.5 | 45 | 56.5 | |
Min–max | 22–73 | 26–71 | 24–73 | |
WBC (109/L) | ||||
Mean ± SD | 8.8 ± 3.3 | 11.8 ± 9.9 | 11.9 ± 15.9 | 0.679 |
Median | 8 | 8 | 6.4 | |
Min–max | 4.5–17 | 5–50 | 1–69 | |
Hemoglobin (g/dL) | ||||
Mean ± SD | 17.4 ± 2.4 | 13 ± 3 .5 | 8.7 ± 2.8 | < 0.001 |
Median | 17.7 | 13 | 8.5 | |
Min–max | 12.3–21 | 8–26 | 3–14.9 | |
Platelet count (109/L) | ||||
Mean ± SD | 294 ± 165 | 1099 ± 470 | 268.5 ± 351.8 | < 0.001 |
Median | 347.5 | 922 | 150.5 | |
Min–max | 32–570 | 455–2433 | 13–1408 | |
JAK2 p. Val617Phe | 9 (64.3) | 13 (50) | 6 (30) | 0.143 |
Splenomegaly, no. (%) | ||||
Positive | 3 (21.4) | 13 (50) | 11 (55.0) | 0.126 |
Negative | 11 (78.6) | 13 (50) | 9 (45) | |
Hepatomegaly, no. (%) | ||||
Positive | 1 (7.1) | 4 (15.4) | 4 (20.0) | 0.527 |
Negative | 13 (92.9) | 22 (84.6) | 16 (80) | |
Fatigue, no. (%) | ||||
Positive | 5 (35.7) | 6 (23.1) | 12 (60) | 0.041 |
Negative | 9 (64.3) | 20 (76.9) | 8 (40) | |
Headache, no. (%) | ||||
Positive | 4 (28.6) | 7 (26.9) | 5 (25) | 1.000 |
Negative | 10 (71.4) | 19 (73.1) | 15 (75) | |
Bleeding events, no. (%) | ||||
Positive | 1 (7.1) | 5 (19.2) | 5 (25) | 0.443 |
Negative | 13 (92.9) | 21 (80.8) | 15 (75) | |
Thrombosis, no. (%) | ||||
Positive | 1 (7.1) | 4 (15.4) | 1 (5) | 0.551 |
Negative | 13 (92.9) | 22 (84.6) | 19 (95) | |
Dizziness, no. (%) | ||||
Positive | 0 (0) | 2 (7.7) | 4 (20) | 0.180 |
Negative | 14 (100) | 24 (92.3) | 16 (80) | |